INNOCAN PHARMA Corp (INNPF) Stock Price & Analysis
INNOCAN PHARMA Corp (INNPF) — price $1.40 (-13.58%), as of the Oct 2, 2026 trading session; market cap $6.30M.
Educational signal · not a buy or sell recommendation · How to read this
INNOCAN PHARMA Corp · INNPF
InnoCan Pharma Corporation is a Canadian pharmaceutical company specializing in the development of CBD-integrated drug delivery platforms, including exosomes and liposomes, for various medical conditions. The company also commercializes branded CBD topical products, operating across the United States, Poland, France, and other international markets.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.40 | |
| Change on the day | -13.58% | |
| 52-week range | $1.40 – $14.26 | |
| Market capitalisation | $6.30M | |
| Shares traded on the day | 114 |
Price & events
Other perspectives
Council score for INNOCAN PHARMA (INNPF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the INNPF film — every key number, told as a short cinematic story
~2 min · open the film
What is INNOCAN PHARMA (INNPF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. INNOCAN PHARMA Corp (INNPF) is the company analyzed here. It employs 11 people and is led by Iris Bincovich. In Q2 FY2026 it reported revenue of $5M and net income of -$33,136. The market values it at $6.30M.
What do the latest results show for INNOCAN PHARMA (INNPF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $5M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $5M | -$33,136 | -$0.01 (diluted) |
| Q1 FY2026 | $6M | -$958,536 | -$0.21 (diluted) |
| Q4 FY2025 | $5M | $2M | $0.44 (diluted) |
| Q3 FY2025 | $7M | -$2M | -$0.43 (diluted) |
What are the financial strengths and risks for INNOCAN PHARMA (INNPF)?
Short answer
The distress and quality screens read Altman Z -0.92 · Piotroski F 3. Trailing ratios: ROE -19.4% · ROA -9.1% · current ratio 4.99 · earnings yield -13.6% · free-cash-flow yield -22.2%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -0.92 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-19.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What has been published about INNOCAN PHARMA (INNPF)?
What Investors Ask About INNOCAN PHARMA (INNPF)
These answers are editorial: 1 of these 8 answers is drawn from the INNPF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is INNPF a good stock to buy?
Stock Expert AI does not rate INNPF buy, sell or hold. INNOCAN PHARMA Corp has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the INNPF stock price today?
The last price recorded on this page for INNOCAN PHARMA Corp (INNPF) is $1.40, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key growth opportunities for INNPF in healthcare?
InnoCan Pharma's primary growth opportunities in the healthcare sector stem from the advancement and commercialization of its proprietary CBD loaded drug delivery platforms.
What are the key factors to evaluate for INNPF?
Evaluate INNPF on fundamentals, analyst consensus, and risk factors. This strategy could significantly de-risk its R&D investments and broaden its impact. Not financial advice.
How frequently does INNPF data refresh on this page?
INNPF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven INNPF's recent stock price performance?
INNOCAN PHARMA Corp (INNPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary R&D focus on advanced CBD drug delivery platforms (exosomes, liposomes). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INNPF overvalued or undervalued right now?
INNOCAN PHARMA Corp (INNPF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research INNPF before investing?
Before investing in INNOCAN PHARMA Corp (INNPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (13 figures)
The 13 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.40 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T19:24:35.517Z. | |
px.change | Change on the day | -13.58% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $6.30M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-01. FMP quote timestamp: 2026-10-01T16:07:43.000Z. Captured from FMP at 2026-10-04T19:24:34.499Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.22 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 114 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $5M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$33,136 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $1.40 – $14.26 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.employees | Employees | 11 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.ceo | Chief executive | Iris Bincovich | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z -0.92 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -19.4% · ROA -9.1% · current ratio 4.99 · earnings yield -13.6% · free-cash-flow yield -22.2% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.